Vaisala’s Q4 turned out to be very strong as the operating result was higher than the company previo...
Duell delivered slightly better figures than we had expected for the seasonally quiet Q1 of its fisc...
22% ARR growth and a solid 11% adj. EBITDA beat '25 guidance raised; adj.
Redeye briefly comments on MedCap releasing preliminary Q4 2024 figures, significantly undershooting...
Redeye is impressed by the strong preliminary Q4 results, demonstrating an EBIT breakeven several qu...
Redeye comments on the recent news regarding Integrum’s partnership with Intelerad.
Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phas...
Duell reported Q1 net sales at EUR 28.3m, just surpassing our forecast of EUR 27.
Redeye takes a positive stance on the news that Sivers is raising SEK108m through a directed share i...
Safello pre-announced key metrics for its Q4 2024 report due 21/02/2025.
Redeye endorses today’s news that Cephagenix has secured funding of up to EUR9m and gives an initial...
Redeye makes a brief comment on today’s news of the CEO replacement.
Redeye strengthens its positive view of Teneo AI following preliminary Q4 figures showing a substant...
Q4e: Clean paper EBIT of ~PLN 10m Paper prices down, demand muted Fair value range of SEK 40-80 Thi...
Redeye leaves a research update following Klaria Pharma’s recent announcement of a licensing agreeme...
Preliminary Q4 EBITA ~40% below FactSet consensus We expect consensus to cut '25 EBITA by ~15% and '...
Northbaze Group AB will receive approximately SEK 5.
Redeye comments on Nanologica following the annonucement of a SEK8.
Redeye comments on Sivers Semiconductors following the announcement that the company will receive an...
Redeye comments on CLS’s recap of 2024 and outlook for 2025-2026.
